• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of Clinical Medicine Research >Budesonide Use and Hospitalization Rate in Crohn’s Disease: Results From a Cohort at a Tertiary Care IBD Referral Center
【24h】

Budesonide Use and Hospitalization Rate in Crohn’s Disease: Results From a Cohort at a Tertiary Care IBD Referral Center

机译：克罗恩病中布地奈德的使用和住院率：三级护理IBD转诊中心的队列结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Budesonide is generally not used for periods > 90 days in Crohn’s disease (CD). We sought to study the association between cumulative outpatient budesonide use in days and hospitalization rate in CD patients seen at our institution.Methods: Using a retrospective cohort study design, we selected CD patients > 19 years old and followed for at least 1 year. Days of outpatient budesonide use were calculated by reviewing outpatient clinic notes. Treatment groups included patients who were not given budesonide, received budesonide from 1 to 90 days, and received budesonide > 90 days. We performed univariate analyses and developed generalized Poisson regression models for rate data to estimate incidence rate ratios (IRRs) and 95% confidence intervals (95% CIs) for CD-related hospitalization.Results: Of 767 CD patients, 664 did not receive budesonide, 45 received budesonide from 1 to 90 days, and 58 received budesonide for > 90 days. Incidence rates of hospitalization in patients who received no budesonide vs. 1 - 90 days of budesonide vs. > 90 days of budesonide were 31, 26, and 19 per 100 person-years, respectively. Adjusted models demonstrated that receiving outpatient budesonide from 1 to 90 days and for > 90 days was associated with a lower likelihood of being admitted for a CD exacerbation (1 - 90 days: IRR 0.85; 95% CI 0.65 - 1.10; > 90 days: IRR 0.71; 95% CI 0.56 - 0.91).Conclusions: Outpatient budesonide use appears to be associated with a lower likelihood of a CD-related hospitalization, notably when used for > 90 days. This association needs to be further assessed before recommending this agent for routine use for > 90 days.J Clin Med Res. 2016;8(10):705-709doi: http://dx.doi.org/10.14740/jocmr2630w
机译：背景：克罗恩病（CD）通常在90天内不使用布地奈德。我们试图研究天数累积的布地奈德门诊使用量与本院CD患者的住院率之间的关系。方法：采用回顾性队列研究设计，我们选择年龄大于19岁且随访至少1年的CD患者。门诊布地奈德使用天数是通过回顾门诊临床笔记来计算的。治疗组包括未接受布地奈德治疗，从1到90天接受布地奈德治疗且接受布地奈德治疗> 90天的患者。我们对数据进行了单变量分析并建立了广义的Poisson回归模型，以评估CD相关住院的发生率（IRR）和95％置信区间（95％CI）。结果：767名CD患者中有664名未接受布地奈德治疗， 1至90天有45位接受布地奈德治疗，而布地奈德接受58天以上的治疗则有58位。没有接受布地奈德治疗的患者的住院率分别为：布地奈德1-90天与布地奈德> 90天的住院率分别为每100人年31、26和19。调整后的模型表明，在1到90天之内接受布地奈德的门诊时间大于90天与CD急性加重的入院可能性降低相关（1- 90天：IRR 0.85; 95％CI 0.65-1.10;> 90天： IRR 0.71; 95％CI 0.56-0.91）。结论：门诊使用布地奈德似乎与CD相关住院的可能性较低，特别是当使用> 90天时。在推荐该药物常规使用> 90天之前，需要进一步评估这种关联。JClin Med Res。 2016; 8（10）：705-709doi：http：//dx.doi.org/10.14740/jocmr2630w

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号